Viewing nowCabalin Capsule 150 mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
HK inno.N Co., Ltd.

MFDS item code 201502555 · Approved 2015.04.28 · Insurance code 640007150
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used to relieve pain caused by peripheral and central neuropathy in adults. It is also used as an adjunct in the treatment of partial seizures in epilepsy to help improve symptoms. Additionally, it is effective in the treatment of fibromyalgia. It is used to improve symptoms of various nerve-related diseases.
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) Neuropathic pain—Peripheral neuropathic pain: Adults: The initial dose may be 150 mg/day. Depending on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. Neuropathic pain—Central neuropathic pain: Adults: The initial dose may be 150 mg/day. Depending on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target dose of 600 mg/day. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’.) Epilepsy: Adults: The initial dose may be 150 mg/day. Depending on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. Fibromyalgia: The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day); based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. Patients with renal impairment: Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the dosing regimen. b: The supplemental dose refers to a dose administered once in addition to the regular dose. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediately administered supplemental dose should be given after each 4-hour hemodialysis session. No dose adjustment is required in patients with hepatic impairment. Elderly patients (65 years and older): Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or actions, so it is important to closely monitor for any abnormal changes in mood or behavior while taking it. Patients who are allergic to any of the ingredients in this medication should not take it, and those with certain genetic disorders should also avoid it. Diabetic patients may need to adjust the dose of blood sugar controlling medications due to weight gain. If symptoms of hypersensitivity such as angioedema occur, the medication should be discontinued immediately. Elderly patients should be cautious during the initial doses as they may experience symptoms such as dizziness or drowsiness. Vision may be blurred or change, and if any abnormal symptoms occur, a consultation with a doctor is advised. Abruptly stopping this medication can result in withdrawal symptoms such as insomnia, headache, and anxiety, so it should be discontinued gradually under a physician's guidance. Because of the potential for drug abuse or dependence, patients with a history of substance abuse should consult their doctor before taking this medication. Patients with impaired kidney function may require dose adjustment. Patients with heart disease should be cautious when taking this medication. Combining with opioid analgesics can increase central nervous system depressant effects, so care should be taken when used together. Patients with respiratory dysfunction or the elderly may be at risk of severe respiratory depression, so doses should be adjusted accordingly. Women of childbearing potential should use effective contraception while taking this medication due to the risk of fetal malformation in early pregnancy. It is advisable to avoid risky activities like driving or operating machinery until dizziness or drowsiness completely subsides. Severe skin reactions may occur rarely, so if any abnormal skin symptoms develop, medication should be stopped immediately and a healthcare provider consulted. Use of this medication during pregnancy may pose risks to the fetus; consult a doctor if pregnant or planning to become pregnant. If breastfeeding, as this medication may be passed through breast milk, consult a doctor about whether to stop breastfeeding or the medication. In cases of overdose, symptoms may include confusion, drowsiness, depression, and seizures, and medical treatment such as hemodialysis may be necessary. This medication should be kept out of the reach of children, and it is safer not to transfer it to another container.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to prevent air or moisture from entering. It should be kept away from direct sunlight in a cool place between 15 and 30 degrees Celsius.
A hard capsule with a white or off-white powder inside, with a white upper and lower part.
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
HK inno.N Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.